Vasopressin antagonism: Potential impact on neurologic disease

Clinical Neuropharmacology

Volumn 29, Issue 2, 2006, Pages 87-93

  Rabinstein, Alejandro A ^a,b  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b NONE   (United States)

Author keywords

Hyponatremia; Vasopressin; Vasopressin receptor antagonists

Indexed keywords

ARGIPRESSIN; CONIVAPTAN; LIXIVAPTAN; TOLVAPTAN; VASOPRESSIN DERIVATIVE; VASOPRESSIN RECEPTOR;

CLINICAL FEATURE; DISEASE CLASSIFICATION; DRUG EFFECT; DRUG TOLERABILITY; HUMAN; HYPONATREMIA; NEUROSURGERY; PRIORITY JOURNAL; REVIEW; ANIMAL; DRUG ANTAGONISM; NEUROLOGIC DISEASE; PATHOPHYSIOLOGY; PHYSIOLOGY; POSTOPERATIVE COMPLICATION; SCHWARTZ BARTTER SYNDROME;

ANIMALS; HUMANS; HYPONATREMIA; INAPPROPRIATE ADH SYNDROME; NERVOUS SYSTEM DISEASES; POSTOPERATIVE COMPLICATIONS; RECEPTORS, VASOPRESSIN; VASOPRESSINS;

EID: 33646912212     PISSN: 03625664     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002826-200603000-00006     Document Type: Review

References (59)

1. Adrogué HJ, Madias NE. Hyponatremia. N Engl J Med. 2000;342:1581-1589.
2. Fried LF, Palevsky PM. Hyponatremia and hypernatremia. Med Clin North Am. 1997;81:585-609.
3. Rabinstein AA, Wijdicks EF. Hyponatremia in critically ill neurological patients. Neurologist. 2003;9:290-300.
4. Albanese A, Hindmarsh P, Stanhope R. Management of hyponatremia in patients with acute cerebral insults. Arch Dis Child. 2001;85:246-251.
5. Soupart A, Decaux G. Therapeutic recommendations for management of severe hyponatremia: current concepts on pathogenesis and prevention of neurologic complications. Clin Nephrol. 1996;46:149-169.
6. Sterns RH, Cappuccio JD, Silver SM, et al. Neurologic sequelae after treatment of severe hyponatremia: a multicenter perspective. J Am Soc Nephrol. 1994;4:1522-1530.
7. Palmer BF, Gates JR, Lader M. Causes and management of hyponatremia. Ann Pharmacother. 2003;37:1694-1702.
8. Kozniewska E, Podlecka A, Rafalowska J. Hyponatremic encephalopathy - some experimental and clinical findings. Folia Neuropathol. 2003;41:41-45.
9. Han D-S, Cho B-S. Therapeutic approach to hyponatremia. Nephron. 2002;92:9-13.
10. Martin RJ. Central pontine and extrapontine myelinolysis: the osmotic demyelination syndromes. J Neurol Neurosurg Psychiatry. 2004;75:iii22-iii28.
11. Gullans SR, Verbalis JG. Control of brain volume during hyperosmolar and hypo-osmolar conditions. Annu Rev Med. 1993;44:289-301.
12. Decaux G, Soupart A. Treatment of symptomatic hyponatremia. Am J Med Sci. 2003;326:25-30.
13. Coenraad MJ, Meinders AE, Taal JC, et al. Hyponatremia in intracranial disorders. Neth J Med. 2001;58:123-127.
14. 2 receptor antagonists. J Mol Endocrinol. 2002;29:1-9.
15. Palm C, Reimann D, Gross P. The role of V2 vasopressin antagonists in hyponatremia. Cardiovasc Res. 2001;51:403-408.
16. Ishikawa S, Schrier RW. Pathophysiological roles of arginine vasopressin and aquaporin-2 in impaired water excretion. Clin Endocrinol. 2003;58:1-17.
17. Robertson GL. Thirst and vasopressin function in normal and disordered states of water balance. J Lab Clin Med. 1983;101:351-371.
18. Bartter FC, Schwartz WB. The syndrome of inappropriate secretion of antidiuretic hormone. Am J Med. 1967;42:790-806.
19. Casulari LA, Costa KN, Albuquerque RC, et al. Differential diagnosis and treatment of hyponatremia following pituitary surgery. J Neurosurg Sci. 2003;47:11-18.
20. Sane T, Rantakari K, Poranen A, et al. Hyponatremia after transsphenoidal surgery for pituitary tumors. J Clin Endocrinol Metab. 1994;79:1395-1398.
21. Cusick JF, Hagen TC, Findling JW. Inappropriate secretion of antidiuretic hormone after transsphenoidal surgery for pituitary tumors. N Engl J Med. 1984;311:36-38.
22. Henry DA, Lawson DH, Reavey P, et al. Hyponatraemia during carbamazepine treatment. Br Med J. 1977;1:83-84.
23. Mewasingh L, Aylett S, Kirkham F, et al. Hyponatraemia associated with lamotrigine in cranial diabetes insipidus. Lancet. 2000;356:656.
24. Matuk F, Kalyanaraman K. Syndrome of inappropriate secretion of antidiuretic hormone in patients treated with psychotherapeutic drugs. Arch Neurol. 1977;34:374-375.
25. De Rivera JLG. Inappropriate secretion of antidiuretic hormone from fluphenazine therapy. Ann Intern Med. 1975;82:811-812.
26. Ajlouni K, Kern MW, Tures JF, et al. Thiothixene-induced hyponatremia. Arch Intern Med. 1974;134:1103-1105.
27. Abbott R. Hyponatremia due to antidepressant medications. Ann Emerg Med. 1983;12:708-710.
28. Wilkinson TJ, Begg EJ, Winter AC, et al. Incidence and risk factors for hyponatremia following treatment with fluoxetine or paroxetine in elderly people. Br J Clin Pharmacol. 1999;47:211-217.
29. Palmer BF. Hyponatremia in patients with central nervous system disease: SIADH versus CSW. Trends Endocrinol Metab. 2003;14:182-187.
30. Dooling E, Winkelman C. Hyponatremia in the patient with subarachnoid hemorrhage. J Neurosci Nurs. 2004;36:130-135.
31. Palmer BF. Hyponatremia with natriuresis in neurosurgical patients [reply to letter]. Nephrol Dial Transplant. 2000;15:1707-1708.
32. Docci D, Cremonini AM, Nasi MT, et al. Hyponatremia with natriuresis in neurosurgical patients [letter]. Nephrol Dial Transplant. 2000;15:1707.
33. Kinzie BJ. Management of the syndrome of inappropriate secretion of antidiuretic hormone. Clin Pharm. 1987;6:625-633.
34. Perks WH, Walters EH, Tams IP, et al. Demeclocycline in the treatment of the syndrome of inappropriate secretion of antidiuretic hormone. Thorax. 1979;34:324-327.
35. Forrest JN Jr, Cox M, Hong C, et al. Superiority of demeclocycline over lithium in the treatment of chronic syndrome of inappropriate secretion of antidiuretic hormone. N Engl J Med. 1978;298:173-177.
36. Decaux G, Brimioulle S, Genette F, et al. Treatment of the syndrome of inappropriate secretion of antidiuretic hormone by urea. Am J Med. 1980;69:99-106.
37. Decaux G, Genette F. Urea for long-term treatment of syndrome of inappropriate secretion of antidiuretic hormone. Br Med J. 1981;283:1081-1083.
38. White MG, Fetner CD. Treatment of the syndrome of inappropriate secretion of antidiuretic hormone with lithium carbonate. N Engl J Med. 1975;292:390-392.
39. Finsterer U, Beyer A, Jensen U, et al. The syndrome of inappropriate secretion of antidiuretic hormone (SIADH)-treatment with lithium. Intensive Care Med. 1982;8:223-229.
40. Tanay A, Yust I, Peresecenschi G, et al. Long-term treatment of the syndrome of inappropriate antidiuretic hormone secretion with phenytoin. Ann Intern Med. 1979;90:50-52.
41. Decaux G, Przedborski S, Soupart A. Lack of efficacy of phenytoin in the syndrome of inappropriate secretion of anti-diuretic hormone of neurological origin. Postgrad Med J. 1989;65:456-458.
42. Wijdicks EF, Vermeulen M, van Brummelen P, et al. The effect of fludrocortisone acetate on plasma volume and natriuresis in patients with aneurysmal subarachnoid hemorrhage. Clin Neurol Neurosurg. 1988;90:209-214.
43. Costello-Boerrigter LC, Boerrigter G, Burnett JC Jr. Revisiting salt and water retention; new diuretics, aquaretics, and natriuretics. Med Clin North Am. 2003;87:475-491.
44. Lee CR, Watkins ML, Patterson JH, et al. Vasopressin: a new target for the treatment of heart failure. Am Heart J. 2003;146:9-18.
45. Trandafir CC, Nishihashi T, Wang A, et al. Participation of vasopressin in the development of cerebral vasospasm in a rat model of subarachnoid haemorrhage. Clin Exp Pharmacol Physiol. 2004;31:261-266.
46. Nishihashi T, Trandafir CC, Wang A, et al. Enhanced reactivity to vasopressin in rat basilar arteries during vasospasm after subarachnoid hemorrhage. Eur J Pharmacol. 2005;513:93-100.
47. 1 vasopressin receptor antagonist SR-49059 on infarction volume and recovery of function in a focal embolic stroke model. Stroke. 2002;33:3033-3037.
48. Gerbes AL, Gulberg V, Gines P, et al. Therapy of hyponatremia in cirrhosis with a vasopressin receptor antagonist: a randomized double-blind multicenter trial. Gastroenterology. 2003;124:933-939.
49. 2-receptor blockade with tolvaptan in patients with chronic heart failure. Results from a double-blind, randomized trial. Circulation. 2003;107:2690-2696.
50. Gheorghiade M, Gattis WA, O'Connor CM, et al. Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure. A randomized controlled trial. JAMA. 2004;291:1963-1971.
51. Saito T, Ishikawa S-E, Abe K, et al. Acute aquaresis by the nonpeptide arginine vasopressin (AVP) antagonist OPC-31260 improves hyponatremia in patients with syndrome of inappropriate secretion of antidiuretic hormone (SIADH). J Clin Endocrinol Metab. 1997;82:1054-1057.
52. 2 receptor antagonist and loop diuretic in humans. Clin Nephrol. 2003;59:164-173.
53. 2 vasopressin antagonist YM087 [abstract]. J Am Soc Nephrol. 1999;10:A0613.
54. 2 receptor antagonist [abstract]. Eur Heart J. 2000;21:345.
55. 2 antagonist conivaptan increases sodium concentration and effective water clearance in hyponatremia [abstract]. J Am Soc Nephrol. 2004;15:356A. Abstract SA-P0254.
56. Vaprisol [package insert]. Deerfield, IL: Astellas Pharma US, Inc.; 2005.
57. 2 antagonist, increased serum sodium and effective water clearance in patients with euvolemic or hypervolemic hyponatremia [abstract]. J Am Soc Nephrol. 2004;15:355A. Abstract SA-P0243.
58. 2 antagonist conivaptan in patients with euvolemic or hypervolemic hyponatremia [abstract]. J Am Soc Nephrol. 2004;15:355A. Abstract SA-P0251.
59. Gross P, Reimann D, Henschkowski J, et al. Treatment of severe hyponatremia: conventional and novel aspects. J Am Soc Nephrol. 2001;12:S10-S14.